Scientists studied the efficacy of a glucagon-like peptide-1 (GLP-1) and estrogen dual agonist (GLP1-E2) in pancreatic islet protection. GLP1-E2 provided superior protection from insulin-deficient diabetes induced by multiple low-dose streptozotocin and by the Akita mutation in mice than a GLP-1 monoagonist.
[Cell Reports Medicine]
6445212
BBBBBBBB
items
1
apa
0
default
asc
1
174004
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/